A partnership between China’s SciNeuro Pharmaceuticals and Swiss pharmaceutical giant Novartis on Monday has revived hopes for treating Alzheimer’s disease.
The deal, worth nearly US$1.7 billion, grants Novartis exclusive worldwide rights to develop and commercialise SciNeuro’s antibody candidates to develop drugs for the progressive brain disease.
SciNeuro’s novel amyloid beta targeted antibody programme leverages proprietary blood-brain barrier shuttle technology to help more of the drug cross…
China’s SciNeuro, Novartis sign US$1.7 billion licensing deal to develop Alzheimer’s drugs
